Cue Biopharma, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report covers events occurring on June 1, 2026, regarding Cue Biopharma, Inc. (Nasdaq: CUE). The filing documents the results of a Special Meeting of Stockholders held on that date to approve corporate governance and equity-related proposals.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate actions and voting results rather than financial performance metrics.
Material Changes and Voting Results
Stockholders voted on three proposals at the Special Meeting. All proposals were approved:
- Proposal 1: Approval of the issuance of common stock upon the exercise of warrants issued in May 2026 related to a licensing transaction and private placement.
- For: 1,782,133
- Against: 113,311
- Abstain: 1,013
- Proposal 2: Approval of the Cue Biopharma, Inc. 2026 Stock Incentive Plan.
- For: 1,261,296
- Against: 632,474
- Abstain: 2,687
- Proposal 3: Approval to adjourn the meeting if necessary to solicit further proxies. This was approved but deemed not necessary as Proposals 1 and 2 passed.
- For: 1,302,751
- Against: 582,084
- Abstain: 11,622
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors. It references the definitive proxy statement filed on May 21, 2026, for a detailed description of the 2026 Stock Incentive Plan.
Key Facts for Investor Verification
- Verify the terms of the May 2026 licensing transaction and private placement that triggered the warrant issuance approved in Proposal 1.
- Review the full text of the 2026 Stock Incentive Plan (Exhibit 10.1) to understand dilution potential and executive compensation structures.
- Confirm the number of shares authorized for issuance under the newly approved 2026 Plan.